Comments
Strides Pharma Science Ltd has received Establishment Inspection Report (EIR) for the inspection conducted by the US Food and Drug Administration (USFDA) in January 2020 at KRS Gardens, Bengaluru.
The inspection was related to specific extended-release applications made from the site, and the receipt of EIR confirms the successful closure of the inspections, the company said in a statement.
KRS Gardens, the company’s flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility is also capable of manufacturing complex formulations of extended-release tablets.
Strides have a large extended-release portfolio for the US and other regulated markets with a capability to manufacture these products at multiple sites, it added.
Strides had recently received EIR for the Bengaluru facility from USFDA for the inspection conducted in March 2020.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.